Andrew H Matthews (Andrew Matthews)

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 14

Top Topics

Acute Myeloid Leukemia

Allogeneic Hematopoietic Stem Cell Transplantation

Tyrosine Kinase

Loop Mediated Isothermal Amplification

Top Venues

Leukemia & lymphoma

American journal of hematology

This page only lists publications with an associated author ORCID identifier.

Publications

Andrew H Matthews, Elena Fenu, Sarah J Skuli, Jaryse C Harris, Adam Bagg, Catherine Lai
Immunohistochemistry-based detection of TP53 mutations in acute myeloid leukemia: a promising high sensitivity diagnostic approach. Leukemia & lymphoma (2024)
Yasmin M Abaza, Eric S Winer, Guru Subramanian Guru Murthy, Rory M Shallis, Andrew H Matthews, Talha Badar, Emily M Geramita, Vamsi K Kota, Alok Swaroop, Peter Doukas, Danielle Bradshaw, Irene B Helenowski, Yingzhe Liu, Hui Zhang, Annie P Im, Mark R Litzow, Alexander E Perl, Ehab Atallah, Jessica K Altman
Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real-world data from eight US academic centers. American journal of hematology 99 (4) (2024)
Yasmin M Abaza, Eric S Winer, Guru Subramanian Guru Murthy, Rory M Shallis, Andrew H Matthews, Talha Badar, Emily M Geramita, Vamsi K Kota, Alok Swaroop, Peter Doukas, Danielle Bradshaw, Irene B Helenowski, Yingzhe Liu, Hui Zhang, Annie P Im, Mark R Litzow, Alexander E Perl, Ehab Atallah, Jessica K Altman
Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real-world data from eight US academic centers. American journal of hematology 99 (4) (2024)
Andrew H Matthews, Elena Fenu, Sarah J Skuli, Jaryse C Harris, Catherine Lai
Immunohistochemistry-based detection of TP53 mutations in acute myeloid leukemia: a promising high sensitivity diagnostic approach. Leukemia & lymphoma (2024)
Andrew H Matthews, Elena Fenu, Sarah J Skuli, Jaryse C Harris, Adam Bagg, Catherine Lai
Immunohistochemistry-based detection of TP53 mutations in acute myeloid leukemia: a promising high sensitivity diagnostic approach. Leukemia & lymphoma 65 (7) (2024)
Dorottya Laczko, Corey Poveda-Rogers, Andrew H Matthews, Oraine Snaith, Selina Luger, Adam Bagg, Gabriel C Caponetti, Jennifer J D Morrissette, Guang Yang
RAD21 mutations in acute myeloid leukemia. Leukemia & lymphoma 65 (7) (2024)
Dorottya Laczko, Corey Poveda-Rogers, Andrew H Matthews, Oraine Snaith, Selina Luger, Adam Bagg, Gabriel C Caponetti, Jennifer J D Morrissette, Guang Yang
RAD21 mutations in acute myeloid leukemia. Leukemia & lymphoma (2024)
Yasmin M Abaza, Eric S Winer, Guru Subramanian Guru Murthy, Rory M Shallis, Andrew H Matthews, Talha Badar, Emily M Geramita, Vamsi K Kota, Alok Swaroop, Peter Doukas, Danielle Bradshaw, Irene B Helenowski, Yingzhe Liu, Hui Zhang, Annie P Im, Mark R Litzow, Alexander E Perl, Ehab Atallah, Jessica K Altman
Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real-world data from eight US academic centers. American journal of hematology 99 (4) (2024)
Yasmin M Abaza, Eric S Winer, Guru Subramanian Guru Murthy, Rory M Shallis, Andrew H Matthews, Talha Badar, Emily M Geramita, Vamsi K Kota, Alok Swaroop, Peter Doukas, Danielle Bradshaw, Irene B Helenowski, Yingzhe Liu, Hui Zhang, Annie P Im, Mark R Litzow, Alexander E Perl, Ehab Atallah, Jessica K Altman
Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real-world data from eight US academic centers. American journal of hematology (2024)
Andrew H Matthews, Alexander E Perl, Selina M Luger, Saar I Gill, Catherine Lai, David L Porter, Sarah Skuli, Ximena Jordan Bruno, Martin P Carroll, Craig W Freyer, Alison Carulli, Daria V Babushok, Noelle V Frey, Elizabeth O Hexner, Mary Ellen Martin, Shannon R McCurdy, Edward A Stadtmauer, Alison W Loren, Vikram R Paralkar, Ivan P Maillard, Keith W Pratz
Real-world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia. American journal of hematology (2023)
Andrew H Matthews, Alexander E Perl, Selina M Luger, Alison W Loren, Saar I Gill, David L Porter, Daria V Babushok, Ivan P Maillard, Martin P Carroll, Noelle V Frey, Elizabeth O Hexner, Mary Ellen Martin, Shannon R McCurdy, Edward A Stadtmauer, Vikram R Paralkar, Ximena Jordan Bruno, Wei-Ting Hwang, David Margolis, Keith W Pratz
Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia. Blood advances 6 (13) (2022)
Andrew H Matthews, Keith W Pratz, Martin P Carroll
Targeting Menin and CD47 to Address Unmet Needs in Acute Myeloid Leukemia. Cancers 14 (23) (2022)
Andrew H Matthews, Keith W Pratz, Martin P Carroll
Targeting Menin and CD47 to Address Unmet Needs in Acute Myeloid Leukemia. Cancers 14 (23) (2022)
Andrew H Matthews, Keith W Pratz, Martin P Carroll
Targeting Menin and CD47 to Address Unmet Needs in Acute Myeloid Leukemia. Cancers 14 (23) (2022)